Establishment and Characterization of a Novel Primitive Yolk Sac Tumour Cell Line, TC587.
AFP
Yolk sac tumour
primitive germ cell tumour
stem cell
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
13
12
2019
revised:
22
12
2019
accepted:
23
12
2019
entrez:
5
2
2020
pubmed:
6
2
2020
medline:
20
3
2020
Statut:
ppublish
Résumé
Yolk sac tumour (YST) is a rare malignant ovarian germ cell tumour that often occurs in young women or adolescents and exhibits an unfavourable outcome. To evaluate the biological behavior of carcinomas in vitro, permanent tumour cell lines are required. However, previously, only a few human YST cell lines have been established. Therefore, we aimed to establish a novel YST cell line. We established a novel YST cell line, TC587, from an adolescent patient with ovarian YST. The cell line expressed AFP and SALL4, the characteristics of YST. In addition, we evaluated somatic mutations using next-generation sequencing and revealed some pathogenic variants, including mutations in the NRAS, KIT, KMT2C, RSF1, and TP53 genes. The newly established TC587 cell line may represent an effective tool for developing treatments and conducting molecular analyses for YST.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Yolk sac tumour (YST) is a rare malignant ovarian germ cell tumour that often occurs in young women or adolescents and exhibits an unfavourable outcome. To evaluate the biological behavior of carcinomas in vitro, permanent tumour cell lines are required. However, previously, only a few human YST cell lines have been established. Therefore, we aimed to establish a novel YST cell line.
MATERIALS AND METHODS
METHODS
We established a novel YST cell line, TC587, from an adolescent patient with ovarian YST.
RESULTS
RESULTS
The cell line expressed AFP and SALL4, the characteristics of YST. In addition, we evaluated somatic mutations using next-generation sequencing and revealed some pathogenic variants, including mutations in the NRAS, KIT, KMT2C, RSF1, and TP53 genes.
CONCLUSION
CONCLUSIONS
The newly established TC587 cell line may represent an effective tool for developing treatments and conducting molecular analyses for YST.
Identifiants
pubmed: 32014918
pii: 40/2/759
doi: 10.21873/anticanres.14007
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
759-766Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.